ClinicalTrials.Veeva

Menu
M

Metropolitan Hospital | 4th Oncology Department

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Telisotuzumab
Lomitapide
Amrubicin
Lurbinectedin
Topotecan
Vemurafenib
Docetaxel
Pembrolizumab
Binimetinib
LGX818

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 8 total trials

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

The purpose of this study is to learn about the effects of three study medicines (encorafenib, binimetinib, and pembrolizumab) given together for the...

Active, not recruiting
Melanoma
Drug: Binimetinib
Drug: Encorafenib

This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lun...

Enrolling
Small Cell Lung Cancer
Drug: Topotecan
Drug: Amrubicin
Locations recently updated

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor,...

Enrolling
Non Small Cell Lung Cancer
Drug: Docetaxel
Biological: Telisotuzumab Vedotin

Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemoth...

Enrolling
Advanced NSCLC
Metastatic Lung Cancer
Combination Product: Cisplatin/Carboplatin
Combination Product: Chemotherapy: Pemetrexed

This is 2-part, randomized, open label, multi-center, parallel group, phase III study comparing the efficacy and safety of LGX818 plus MEK162 to vemu...

Active, not recruiting
Melanoma
Drug: LGX818
Drug: vemurafenib

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that overexpress c-Met (c-Met+) best suited for teliso...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Telisotuzumab vedotin

Trial sponsors

AbbVie logo
Pfizer logo
A
Daiichi Sankyo logo
Mirati Therapeutics logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems